Person: PEHLİVAN, YAVUZ
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
PEHLİVAN
First Name
YAVUZ
Name
42 results
Search Results
Now showing 1 - 10 of 42
Publication Disease duration and hla-b27 positivity alter longterm retention rate of certolizumab pegol in patients with psoriatic arthritis(Bmj Publishing Group, 2021-06-01) Koca, S. S.; Pehlivan, Y.; Akar, S.; Senel, S.; Karadeniz, H.; Sosyal, O.; Yazici, A.; Yilmaz, S.; Sagir, R. Piskin; Inanc, N.; Karatas, A.; Cetin, G. Yildirim; Onen, F.; Pehlivan, Y.; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; 0000-0002-3734-1242; 0000-0003-4665-3421; 0000-0003-2167-4509; 0000-0002-6725-4182; 0000-0001-9680-7535; 0000-0002-6341-2622; AAT-3636-2020; AAA-8970-2021; E-7046-2016; HTP-6798-2023; HJY-2666-2023Publication Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic(TÜBİTAK, 2021-01-01) Kalyoncu, Umut; Pehlivan, Yavuz; Akar, Servet; Kaşifoğlu, Timuçin; Kimyon, Gezmiş; Karadağ, Ömer; Dalkılıç, Ediz; Ertenli, Ali İhsan; Kılıç, Levent; Ersözlü, Duygu; Beş, Cemal; Emmungil, Hakan; Mercan, Rıdvan; Ediboğlu, Elif Durak; Kanıtez, Nilüfer; Bilgin, Emre; Çolak, Seda; Koca, Süleyman Serdar; Gönüllü, Emel; Küçükşahin, Orhan; Coşkun, Nihan; Yağız, Burcu; Kiraz, Sedat; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0002-3734-1242; 0000-0003-1372-1555; 0000-0001-5184-4404; 0000-0003-1185-5816; 0000-0002-2260-4660; 0000-0003-4995-430X; 0000-0002-6990-4206; W-7332-2019; AAK-7851-2021; AAD-5448-2019; AAZ-5845-2021; AAG-8227-2021; C-8092-2015; JQW-5031-2023; GZA-3287-2022Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.Publication Attitudes of patients with a rheumatic disease on drug use in the COVID-19 pandemic(BMC, 2021-09-03) Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Dalkılıç, Ediz; COŞKUN, BELKIS NİHAN; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı; 0000-0003-0298-4157; AAG-8227-2021; CMF-4757-2022Background Anti-rheumatic drugs can increase the predisposition to infection, and patients may be unaware of continuing their treatment during the COVID-19 pandemic. Objective This study aimed to assess whether patients maintain their treatment for rheumatic conditions during the pandemic period and determine the factors responsible for discontinuation. Methods Patients were randomly selected from the prospectively collected database of our tertiary referral center. The patients were interviewed by telephone through a standardized closed-ended questionnaire, which is targeting the continuity of the treatment plan and the considerations related to the individual choice. The patients were asked whether they hesitated to visit the hospital for follow-up or intravenous drug administration. Results A total of 278 patients completed the questionnaire. While 62 of the patients (22.3%) had reduced or interrupted the treatment, only 11 patients (3.9%) stopped the treatment completely. A significant difference was observed between the duration of illness and the discontinuation of treatment. (p = 0.023) There was a significant difference in disease activity between the group that stopped treatment and continued treatment. (p = 0.001) There was no statistically significant difference in other demographic characteristics. One hundred thirty-five patients (48.6%) made the treatment decision by themselves, and 80% continued the treatment. Reasons for stopping the treatment were anxiety (48.4%), not being able to go to the hospital for intravenous treatment (45.1%), and not being able to find the drug (6.5%). Conclusion Since patients with long-term illnesses were found to be significantly more likely to stop their treatment, this group of patients should be monitored.Publication Use of biological dmards in patients with adult-onset still's disease: Results from Turkbio registry(BMJ, 2020-06-01) Yazıcı, A.; Dalkılıç, Hüseyin Ediz; Birlik, M.; Öztürk, M. A.; Akar, S.; Göker, B.; Pehlivan, Yavuz; Şenel, S.; Cefle, A.; Onen, F.; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Ramotoloji Bölümü; JHC-5173-2023; AAG-8227-2021Publication Do comorbidities impact persistence of first tumor necrosis factor inhibitor treatment in rheumatoid arthritis? Data from Turkbio(BMJ Publishing Group, 2020-06-01) İnel, T. Yüce; Kocaer, S. B.; Erez, Y.; Gülle, S.; Karakaş, A.; Avşar, A. Köken; Uslu, S.; Can, G.; Sarı, I.; Birlik, M.; Dalkılıç, E.; Pehlivan, Y.; Akar, S.; Göker, B.; Çetin, G. Yıldırım; Haznedaroğlu, S.; Yavuz, S.; Pırıldar, T.; Direskeneli, H.; Akkoç, N.; Önen, F.; Turkbio Registry Group; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; AAG-8227-2021; JHC-5173-2023Publication Are there any differences between adult-onset rheumatoid arthritis patients and late-onset rheumatoid arthritis patients in terms of use of biological drugs and drug retention rate? Results from the Turkbio registry(Bmj Publishing Group, 2020-06-01) Yazici, A.; Cefle, A.; Can, G.; Senel, S.; Koca, S. S.; Inanc, N.; Goker, B.; Yilmaz, S.; Akar, S.; Soysal, O.; Ozturk, M. A.; Sari, I.; Direskeneli, H.; Onen, F.; Dalkilic, E.; DALKILIÇ, HÜSEYİN EDİZ; Pehlivan, Y.; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; AAG-8227-2021Publication Do comorbidities decrease the first tnf-inhibitor retention and treatment response in axial spondyloarthritis patients? Data from Turkbio(BMJ Publishing Group, 2020-06-01) Erez, Y.; Karakaş, A.; Kocaer, S. B.; İnel, T. Yüce; Gülle, S.; Avşar, A. Köken; Uslu, S.; Can, G.; Sarı, I.; Birlik, M.; Dalkılıç, E.; Pehlivan, Y.; Şenel, S.; Akar, S.; Koca, S. S.; Tufan, A.; Yazıcı, A.; Yılmaz, S.; İnanç, N.; Solmaz, D.; Akkoç, N.; Önen, F.; TURKBIO Study Group; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; AAG-8227-2021; JHC-5173-2023Publication Long-term survival of the first biologic treatment in psoriatic arthritis and the effect of the selected treatment on drug survival; Turkbio registry(BMJ, 2020-06-01) Kocaer, S. B.; İnel, T. Yüce; Erez, Y.; Avşar, A. Köken; Uslu, S.; Karakaş, A.; Gülle, S.; Can, G.; Sarı, I.; Birlik, M.; Dalkılıç, E.; Pehlivan, Y.; Akar, S.; Cefle, A.; Öztürk, M. A.; Yolbaş, S.; Yılmaz, N.; Erten, S.; Akkoç, N.; Önen, F.; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; JHC-5173-2023; AAG-8227-2021Publication Rheumatology patients' attitude regarding Ramadan and fasting(Wiley, 2020-05-27) Pehlivan, Seda; Pehlivan, Yavuz; Yağız, Burcu; Coşkun, Belkıs Nihan; Ermurat, Selime; Dalkılıç, Ediz; PEHLİVAN, SEDA; PEHLİVAN, YAVUZ; YAĞIZ, BURCU; COŞKUN, BELKIS NİHAN; Ermurat, Selime; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Sağlık Bilimleri Fakültesi/Hemşirelik Bölümü.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; 0000-0002-1670-0672; 0000-0003-0298-4157; 0000-0001-9945-8940; ABG-1164-2020; AAG-8227-2021; JQW-5031-2023; B-5037-2017; ABE-4424-2022; AAG-7155-2021Objective Fasting may lead to some problems in patients who have to use drugs on a regular and continuous basis. The objective of this study is to identify rheumatology patients' attitudes toward Ramadan and fasting. Method The descriptive and cross-sectional study was conducted with 374 patients. The study data were collected using a questionnaire form. SPSS was used and percentage and Chi-square analyses were performed. Results It was determined that 56.1% fasted during Ramadan. When asked about the effect of fasting on the disease, 88.4% of those who fasted answered "it had no effect", and 80.1% of those that did not fast said "it affected negatively" (P < .05). It was determined that 41.9% of the fasting patients did not visit the doctor during Ramadan, 52.9% continued using their drugs without any change, and 73.3% did not ask for information on fasting. The rate of patients who were informed by the doctor without any request for information was found to be only 9% (P < .05). Conclusion It was determined that more than half of the rheumatology patients fasted, the majority of these patients thought that it would not affect their disease, and the rate of request for information from the doctor was low. It is considered that a drug program could be prepared for fasting individuals who are willing to fast, in which drugs are taken between theIftarandSuhurtimes, and patients can safely fast without any additional risk to their disease.Publication Leflunomide as a concomitant dmard choice for the biological treatment era of rheumatoid arthritis(Wiley, 2018-09-01) Kimyon, Gezmiş; Kiraz, Sedat; Ertenli, İhsan; Küçükşahin, Orhan; Dalkılıç, Ediz; Beş, Cemal; Kanitez, Nilüfer Alpay; Kaşifoğlu, Timuçin; Emmungil, Hakan; Coşkun, Belkıs Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çınar, Muhammet; Ateş, Askin; Akar, Servet; Bakırlı, Duygu Ersözlü; Yazısız, Veli; Bilge, Nazife Şule Yaşar; Tufan, Müge Aydın; Mercan, Rıdvan; Karadağ, Ömer; Keleşoğlu, Ayşe Bahar; Gercik, Onay; Öz, Burak; Akar, Zeynel Abidin; Yılmaz, Sedat; Turan, Sezin; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıç, Levent; Erten, Şükran; Tekgöz, Emre; Taşçılar, Koray; Kalyoncu, Umut; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; YAĞIZ, BURCU; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Ramotoloji Bölümü; 0000-0003-0298-4157; JQW-5031-2023; AAG-7155-2021; AAG-8227-2021; CMF-4757-2022